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Current concepts in the treatment of 
hereditary ataxias
Conceitos atuais no tratamento das ataxias hereditárias
Pedro Braga-Neto1,2, José Luiz Pedroso2, Sheng-Han Kuo3, Marcondes C. França Junior4, Hélio Afonso 
Ghizoni Teive5, Orlando Graziani Povoas Barsottini2
Ataxia is a disorder of balance and coordination and may 
be classified in different forms1. Hereditary ataxias (HA) rep-
resents an extensive group of clinically and genetically het-
erogeneous neurodegenerative diseases, characterized by 
progressive ataxia combined with extra-cerebellar and multi-
systemic involvements, including peripheral neuropathy, py-
ramidal signs, movement disorders, seizures, and cognitive 
dysfunction1. HA are divided by different inheritance patterns, 
such as, autosomal recessive, autosomal dominant, X-linked, 
and mitochondrial ataxias1. In this group of HA we can add 
two other forms of ataxia: hereditary episodic ataxias (EA) and 
congenital ataxias (CA)1. There is no effective treatment for HA, 
and management remains supportive and symptomatic.
SYMPTOMATIC TREATMENT
Autosomal recessive ataxias 
Autosomal recessive cerebellar ataxias are a group of het-
erogeneous disorders, usually caused by the loss function of 
key enzymes and/or functional proteins in the metabolic path-
ways of lysosomes and/or mitochondria2,3. Therefore, several 
mechanism-based therapies are available to correct the under-
lying defective metabolic pathways. Friedreich’s ataxia (FRDA) 
is the most common autosomal recessive cerebellar ataxia and 
therapy this condition has been extensively reviewed4.
Therefore, we will focus on the treatment for the fol-
lowing autosomal recessive ataxias that have known 
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AbSTRACT
Hereditary ataxias (HA) represents an extensive group of clinically and genetically heterogeneous neurodegenerative diseases, characterized 
by progressive ataxia combined with extra-cerebellar and multi-systemic involvements, including peripheral neuropathy, pyramidal signs, 
movement disorders, seizures, and cognitive dysfunction. There is no effective treatment for HA, and management remains supportive and 
symptomatic. In this review, we will focus on the symptomatic treatment of the main autosomal recessive ataxias, autosomal dominant 
ataxias, X-linked cerebellar ataxias and mitochondrial ataxias. We describe management for different clinical symptoms, mechanism-
based approaches, rehabilitation therapy, disease modifying therapy, future clinical trials and perspectives, genetic counseling and 
preimplantation genetic diagnosis. 
Keywords: hereditary ataxias, treatment, rehabilitation therapy, disease modifying therapy. 
RESuMO
As ataxias hereditárias representam um grupo complexo de doenças neurodegenerativas, e se caracterizam por ataxia cerebelar 
progressiva, associada a sinais e sintomas extra-cerebelares e sistêmicos, os quais incluem: neuropatia periférica, sinais piramidais, 
distúrbios do movimento, convulsões e disfunção cognitiva. Não existe um tratamento efetivo para a cura das ataxias hereditárias. Até 
o momento os tratamentos disponíveis são apenas sintomáticos. Nesta revisão vamos abordar tratamento sintomático das principais 
ataxias autossômicas recessivas, ataxias autossômicas dominantes, ataxias ligadas ao X e ataxias mitocondriais. Descrevemos os 
diferentes sintomas, abordagens terapêuticas baseadas no mecanismo fisiopatológico, terapia de reabilitação, terapia modificadora da 
doença, futuros ensaios clínicos, perspectivas, níveis de evidência, aconselhamento genético e diagnóstico genético pré-implantacional.
Palavras-chave: ataxias hereditárias, tratamento, terapia de reabilitação, terapia modificadora da doença.
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mechanism-based treatment for different clinical symptoms: 
ataxia with vitamin E deficiency (AVED), abetalipoprotein-
emia, Refsum’s disease, Niemann-Pick type C (NPC), cere-
brotendinous xanthomatosis (CTX), ataxia associated with 
coenzyme Q10 (CoQ10) deficiency, and glucose transporter 
type 1 (Glut1) deficiency syndrome5,6,7,8,9,10. Table 1 describes 
the main current symptomatic treatment proposed for au-
tosomal recessive cerebellar ataxia. In addition to cerebel-
lar ataxia, patients with these autosomal recessive ataxias 
usually have peripheral neuropathy (AVED, abetalipopro-
teinemia, Refsum’s disease, and CTX), retinitis pigmentosa 
(AVED, abetalipoproteinemia and Refsum’s disease), move-
ment disorders (dystonia in AVED, NPC and Glut1 deficien-
cy syndrome, and head tremor in AVED), other neurological 
impairment (swallowing problem in NPC, cataplexy and ep-
ilepsy in Glut1 deficiency syndrome, impaired cognition in 
NPC and CTX), and other systematic symptoms (steatorrhea 
in abetalipoproteinemia, ichthyosis and cardiac arrhythmia 
in Refsum’s disease, and tendon xanthoma in CTX)3,5,6,8,10,11-14. 
These disorders are relatively rare and large-scaled ran-
domized, controlled clinical trials are usually not available. 
Nonetheless, successful treated cases can provide guidelines 
to manage these rare disorders.
Ataxia
Treatment of the underlying metabolic abnormality 
in autosomal recessive ataxias could usually lead to sta-
bilization or improvement of ataxic symptoms. Twenty-
four patients with AVED treated with oral vitamin E 
(800-1200 mg/day) for   12 months had normalization of 
vitamin E levels and significant improvement in cerebel-
lar ataxia11. Vitamin E was also employed to treat abet-
alipoproteinemia5. Patients were treated with large doses 
of oral 30-88mg/kg/day vitamin E, 10,500- 29,000 IU/day 
vitamin A, and 1.5-45 IU/day vitamin K for 9-15 years and 
had a normalized blood vitamin E level and the stabiliza-
tion of ataxic symptoms5.
Refsum’s disease is associated with excessive phytanic 
acid. Therefore, diet modification to decrease the intake of 
phytanic acid or plasma exchange has been recommended. 
Low phytanic acid diet (<10mg/day, no green fruits and veg-
etables that contain phytol) in combination with plasma ex-
change lead to improvement of ataxic symptoms12. Plasma 
phytanic acid levels and clinical symptoms might improve 
only after several month of diet modification12. 
Miglustat is a glucosylceramide synthase inhibitor 
that reduces the accumulating glycolipids8. NPC patients 
treated with miglustat 200mg three times a day had slow-
er deterioration of ambulatory function and disease sta-
bilization15. Therefore, early diagnosis is crucial for NPC 
patients12.
CTX is a cholesterol metabolism disorder and the 
treatment involves the intervention on the cholesterol 
biosynthetic pathway. Chenodeoxycholic acid (CDCA) 
750mg/day has been used to treat CTX. A combination of 
CDCA and statins have been proposed, which effectively 
normalized the blood bile acid biochemistry but did not 
improve cerebellar ataxia16. LDL apheresis was also effec-
tive in reducing the cholestanol levels without dramatic 
effects in ataxic symptoms16. 
Ataxia associated with CoQ10 deficiency can be divid-
ed into primary and secondary CoQ10 deficiency.  Primary 
CoQ10 deficiency is caused by mutations of genes directly in-
volving in CoQ10 synthetic pathways, such as COQ2, COQ9, 
PDSS1/2, and ADCK3. Secondary CoQ10 deficiency is asso-
ciated with other genetic mutations such as aprataxin and 
mitochondrial genes17. High dose CoQ10 supplementation 
(30 mg/kg/day) has been shown to be effective to treat ataxia 
associated with CoQ10 deficiency18. 
Finally, cerebellar ataxia associated with Glut1 de-
ficiency syndrome can be treated with ketogenic diet10. 
Alternatively, modified Atkins diet with low carbohydrate 
and high protein and fat content has been shown to im-
prove ataxia symptoms in patients with Glut1 deficiency. 
Table 1. Summary of main symptomatic treatment for patients with autosomal recessive hereditary ataxias.
Autosomal recessive ataxia Symptomatic treatment Level of evidence/ Grade of recommendation
Friedreich ataxia Idebenone 5-20 mg/kg day or CoQ10 30 mg/kg day Class I / A
Ataxia with vitamin E deficiency Vitamin E supplementation Class III / B
Abetalipropoteinemia Vitamin E supplementation 150 mg/kg; Vitamin A;  Medium-chain triglyceride supplement and/or low fat diet Class IV / Good practice point
Refsum’s disease Diet modification to decrease intake of phytanic acid; Plasmapheresis Class IV / Good practice point
Niemann-Pick type C Miglustat Class III / B
Cerebrotendinous xanthomatosis Chenodeoxycholic acid 750 mg/day, HMG-CoaA reductors Class III / C
Ataxia associated with CoQ10 deficiency CoQ10 supplementation 30 mg/kg/day Class IV / Good practice point
Glut1 deficiency syndrome Ketogenic diet Class III / C
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Alpha lipoic acid can facilitate glucose transport and has 
been proposed to treat Glut1 deficiency19.
Peripheral neuropathy
Peripheral neuropathy is frequent in autosomal reces-
sive cerebellar ataxic disorders. Physiological studies showed 
improvement of motor and sensory conduction velocity in 
1 AVED patient treated with vitamin E. A high dose of vi-
tamin A and vitamin E supplementation could lead to im-
provement of sensory examination in abetalipoproteinemia 
patients. In Refsum’s disease, low phytanic acid diet and plas-
ma exchange could consistently lead to either stabilization 
or improvement of peripheral neuropathy and distal mus-
cle strength in several reports6. Despite the inconsistency of 
CDCA to treat ataxia in CTX, peripheral neuropathy seems to 
be more responsive to CDCA treatment in both clinical and 
physiological assessment, at least in a subset of the patients.
Movement disorders
Dystonia and head tremor are the common clinical fea-
tures for AVED5. Vitamin E supplementation was reported to 
be helpful in AVED patients with dystonia. Head tremor in 
AVED did not improve after vitamin E therapy11. Miglustat 
was recommended to treat dystonic symptoms in CTX14. 
Ketogenic diet and modified Atkins diet were effective to 
treat dystonia in Glut1 deficiency10. 
Generalized dystonia can be treated with trihexyphe-
nidyl and benzodiazepine whereas cervical dystonia can 
be treated with botulinum toxin injections in AVED and 
NPC14. Parkinsonism suggesting nigrostriatal dysfunc-
tion should be treated with levodopa. Propranolol and 
primidone should be tried in patients with postural and 
action tremor. 
Other neurological symptoms
Visual symptoms are common in autosomal recessive 
cerebellar ataxias but the responses to therapy are generally 
poor. Retinitis pigmentosa is common in AVED and abetali-
proproteinemia15. However, retinitis pigmentosa seemed not 
to improve on vitamin E replacement in these disorders, and 
patients could develop retinitis pigmentosa while on thera-
py. Cataract in NPC did not improve with low phytanic acid 
diet and plasma exchange. Miglustat consistently improved 
swallowing functions in NPC patients in multiple studies20. 
Epilepsy is very common in Glut1 deficiency syndrome and 
diet modifications are highly effective in either reducing or 
even eliminating the seizures in these patients10.  Cataplexy 
could be seen in NPC patients also but the responses to mi-
glustat were not impressive; instead, the conventional ther-
apy such as tricyclic antidepressants or central stimulants 
should be used14. Finally, CDCA and miglustat have been re-
ported to be beneficial to cognitive function in NPC and CTX 
patients, respectively.
Non-neurological symptoms
Non-neurological symptoms could also impact the qual-
ity of life in patients with autosomal recessive cerebellar 
ataxias and proper treatment is also important. Vitamin sup-
plementation can improve the growth rate in the pediatric 
patients with abetaliproproteinemia. Medium-chain triglyc-
eride supplement and/or low fat diet can help with steat-
orrhea5. Ichthyosis and cardiac arrhythmia are common in 
Refsum’s disease and can be effectively treated with low phy-
tanic acid diet and plasmapheresis6. Finally, the size of ten-
don xanthoma did not seem to regress with CDCA therapy 
in CTX patients. 
Autosomal dominant cerebellar ataxias 
There are a few randomized trials for symptoms treat-
ment in autosomal dominant ataxias. Autosomal dominant 
cerebellar ataxias are divided in two main groups: spinocer-
ebellar ataxias (SCAs) and episodic ataxias (EAs). The role 
for symptomatic treatment on autosomal dominant atax-
ias is divided into the following symptoms: ataxia, other 
Table 2. Main symptomatic treatment proposed for patients with autosomal dominant hereditary ataxias.
Symptomatic treatment Hereditary ataxia type Level of evidence / Grade of recommendation
Riluzole 100 mg/ day SCAs and other etiologies (recessive and sporadic) Class II / B
Varenicline 1 mg twice day SCA3 Class II / B
Buspirone 30 mg twice daily SCAs Class III / C
Oral zync 50 mg/ day SCA3 Class I / B
Insulin-like growth factor-1 SCA3 Class III / C
Acetazolamide 250 mg – 1000 mg EA2 Class III / C
4-aminopyridine 5 mg 3 times a day EA2 Class II / A
Mexiletine and Carbamazepine SCA3  (pain and cramps) Class III /C
Botulinum toxin type  A SCA3 (dystonia and spasticity) Class  III / C
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movement disorders, spasticity, pain and cramps. Table 2 de-
scribes the main symptomatic treatment proposed for auto-
somal dominant cerebellar ataxia. A specific topic on motor 
rehabilitation will also be discussed21.
Ataxia
One of the first proposed treatments for cerebellar symp-
toms is riluzole. This drug acts opening small-conductance 
potassium-channels, exerting an important regulatory ef-
fect on the firing rate of neurons on deep cerebellar nuclei. 
As a result, riluzole may reduce neuronal hyperexcitability. 
A study evaluated 40 patients with different cerebellar atax-
ias and the number of patients with a 5-point ICARS decrease 
was significantly higher in the riluzole group (100 mg/day) 
comparing to placebo. Although these findings may indicate 
potential effectiveness, experience of many ataxic clinics is 
less promising22. Recently, Romano et al. observed a decrease 
in SARA scale in patients with different cerebellar ataxias us-
ing riluzole, but longer studies and disease-specific trials are 
needed to confirm whether these findings can be applied in 
clinical practice23. 
Recently, a phase 2 study assessed the safety and ef-
ficacy of lithium carbonate (0.5-0.8 milliequivalents 
per liter) in patients with SCA3. Mean Neurological 
Examination Score for the Assessment of Spinocerebellar 
Ataxia (NESSCA) after 48 months did not differ between 
groups as well as the SARA scores24.
A randomized double-blind study evaluated the effect 
and safety of oral zinc (50mg) supplementation for 36 pa-
tients with SCA2. A mild decrease in SARA scores for gait, 
posture, stance and alternating hand movements and a re-
duced of saccadic latency were observed. The treatment was 
also safe and well tolerated25. 
Varenicline was also studied. This drug is  a partial α4β2 
agonist neuronal nicotinic acetylcholine receptor used for 
smoking cessation. A trend toward improvement in SARA 
total score in the varenicline group of SCA3 patients was ob-
served. Considerable side effects were detected with nausea 
the most common one26.
The prominent serotoninergic innervation of the cerebel-
lum could be a promising therapeutic for the symptomatic 
of ataxia. It is well known that a deficit of serotonin has been 
proposed as the neurochemical basis of several ataxias. The 
use of buspirone for the treatment of ataxia has been evaluat-
ed in several studies. Buspirone was not shown to be superior 
to placebo in the treatment27. Moreover, a recent experimen-
tal mouse model study of SCA3 described that citalopram, 
another a selective serotonin reuptake inhibitor, significant-
ly reduced ataxin 3 neuronal inclusions and astrogliosis, res-
cued diminished body weight and strikingly ameliorated mo-
tor symptoms, becoming a promising therapeutic target for 
SCA3 patients.
The insulin-like growth factor-1 (IGF-1) performs impor-
tant neuromodulatory functions in the central nervous system. 
Taking this theory in mind, a 2-year prospective clinical trial 
was conducted in patients with SCA3 and SCA7 with subcu-
taneous IGF-1 treatment. The treatment with 50 μg/kg/twice a 
day sc of IGF-1 resulted in improved SARA of SCA3 patients 
after 8 months of treatment. Unfortunately, as this study was 
uncontrolled, it could no exclude a placebo effect28.
Besides SCAs, episodic ataxias (EA) are a diverse group of 
autosomal dominant cerebellar ataxias characterized by at-
tacks of imbalance and incoordination. Several different drugs 
have been reported to improve symptoms of EA1 and EA2. 
Carbamazepine, acetazolamide, valproic acid and lamotrigi-
ne have been reported to be effective for EA1. Acetazolamide 
and the potassium channel blocker 4-aminopyridine seems 
to be effective in EA229,30. 
Other movement disorders 
Movement disorders are quite common in SCAs and may 
be a prominent symptom. Some patients with SCA3 may 
have a levodopa-responsive-Parkinsonism31,32. Other drugs 
should be tried: anticholinergics, benzodiazepines, baclofen 
and carbamazepine. Botulinum toxin injection may be used 
in focal or segmental cases of dystonia31.  
Sleep disorders
Sleep disorders have already been recognized as one of 
the most important non-motor manifestations in SCAs. 
The main described sleep disorders includes: restless leg syn-
drome (RLS), REM sleep behavior disorder (RBD), excessive 
daytime sleep (EDS), insomnia and sleep apnea33. The general 
recommendation of pharmacological and non-pharmacolog-
ical treatment should be addressed as in other diseases.
Pain, cramps and spasticity 
Symptomatic treatment for pain, cramps and spasticity are 
not well studied in patients with SCA. Pain is more frequent 
musculoskeletal, but in a smaller subset may be related to dysto-
nia or neuropathy. These patients may have chronic daily pain, 
specially evolving back and legs34. Improvement of pain may 
be obtained with usual doses of baclofen, cyclobenzaprine and 
amitriptyline. Carbamazepine and mexiletine lead to improve-
ments in intensity and frequency of cramps. Sulfamethoxazole-
trimethoprim and baclofen were also described to ameliorate 
spasticity and rigidity in patients with SCA335. Botulinum toxin 
injection may improve spasticity in patients with SCAs31.
Psychiatric symptoms
Psychiatric symptoms are very common in SCA. A recent 
systematic review described a great number of depressive 
and anxiety symptoms with important difference of the pro-
file according to the subtype of SCA. A previous cohort study 
with 526 patients described worse quality of life in patients 
with depressive symptoms. As a result, specific approach-
es with psychotherapy and antidepressants should be per-
formed in patients with SCA. 
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X-linked cerebellar ataxias (XLCA)
X-Linked Cerebellar Ataxias (XLCA) are a heterogeneous 
group of genetic disorders with onset in early childhood or 
adulthood. The “hallmarks” are cerebellar dysgenesis associ-
ated with imbalances on the X chromosome or gene muta-
tions. The neurological features of XLCA include hypotonia, 
developmental delay, intellectual impairment and ataxia36.
The best characterized phenotypical forms are X-linked 
syndromes with associated cerebellar hypoplasia due to 
OPHN (X-linked mental retardation with cerebellar hypo-
plasia and distinctive facial appearance), CASK (cognitive 
deficiency, microcephaly, hypotonia and optic nerve hypo-
plasia), SLC9A6 (Syndromic X-linked mental retardation, 
Christianson type gene mutations) and ABCB7 (X-linked sid-
eroblastic anemia and ataxia)37.
There are no specific or curative treatments for XLCA and 
the optimal management is directed to provide better qual-
ity of life with comprehensive rehabilitation program, includ-
ing interdisciplinary care such as occupational and physical 
therapy, for behavioral and cognitive impairment and motor 
incoordination. Speech therapy may benefit patients with 
dysarthria and dysphagia37.
Fragile X-associated Tremor/Ataxia syndrome (FXTAS) 
is a late-onset neurodegenerative disorder characterized by 
adult-onset progressive intention tremor and gait ataxia. 
It affects more than 33% of male and 10% of female carriers 
of expanded CGG triplets alleles in the premutation range 
(50-200 repeats) of the FMR1 gene38.
There are no effective therapies for the treatment of 
FXTAS. There is one reported clinical trial for FXTAS treat-
ment utilized memantine and the results suggested that 
this drug may have beneficial effects on verbal memory39. 
Primidone and propranolol may improve the intention trem-
or and selective serotonin and selective norepinephrine 
reuptake inhibitors are effective for anxiety and depression. 
Recently, deep brain stimulation (DBS) has shown favorable 
outcome for tremor and in few cases for ataxia, especially bi-
lateral DBS in VoP/zona incerta40,41.
Mithocondrial ataxias 
Mitochondrial diseases are clinically heterogeneous dis-
orders resulted from dysfunction of the mitochondrial respi-
ratory chain, which is the final common pathway for aerobic 
metabolism. As a result, tissues that are highly dependent on 
aerobic metabolism are preferentially involved in mitochon-
drial disorder. Regarding nervous system, the most common 
manifestations are encephalopathy, seizures, dementia, mi-
graine, stroke-like episodes, ataxia, spasticity, chorea and my-
opathy42. One of the most common manifestations of mito-
chondrial diseases is ataxia. 
The management of mitochondrial diseases is usually 
supportive which includes:  medications for diabetes mellitus, 
cardiac pacing, ptosis correction, intraocular lens replace-
ment for cataracts, cochlear implantation for sensorineural 
hearing loss and symptomatic treatment for spasticity, cho-
rea and epilepsy43. A great number of vitamins and co-factors 
have been used in individuals with mitochondrial disorders, 
although a recent Cochrane systematic review did not iden-
tify clear evidence supporting the use of any intervention in 
mitochondrial disorders43. Some patients may have subjec-
tive benefit on treatment with CoQ10. As previously men-
tioned, CoQ10 and idebenone is specifically indicated in per-
sons with defects of CoQ10 biosynthesis and FRDA. 
REHAbILITATION THERAPY 
Rehabilitation therapy is not well studied in hereditary 
ataxias. Table 3 describes the main rehabilitation strategies 
in hereditary ataxias. Physical therapy, speech therapy and 
occupational therapy are often recommended in patients 
with SCA in order to minimize dependency and decrease 
secondary motor complications. SCA patients have signifi-
cant static and dynamic balance impairment, high risk of fall 
with a great impact in the ability to function43. A recent sys-
tematic review evaluated this approach in patients with he-
reditary ataxias. Physical therapy may lead to improvement 
in ataxia symptoms and daily life functions; occupational 
therapy may improve global function status and diminish 
symptoms of depression. Conventional physical therapy ex-
ercises, treadmill training, relaxation and biofeedback thera-
py, computer-assisted training and supervised sports are one 
of the intervention approaches.  Intensive rehabilitation ther-
apy combining physical therapy and occupational may pro-
vide the best results44. An intensive coordinative therapy with 
3 sessions of 1hour per week has been described as effective 
plan45. Another recent review considered different training 
strategies for spinocerebellar ataxia patients and individual-
ly tailored according to each individual’s ataxia type, disease 
stage, and personal training preferences. For very early stages 
of ataxia, sportive exercises might be selected which place 
high challenges to the coordination system, for example, ta-
ble tennis, squash, or badminton. Virtual reality rehabilita-
tion systems like XBOX Kinect games or Wii games could be 
use as complementary strategies. In mild-to-moderate atax-
ia stages, a coordinative physiotherapy program may include 
the training of secure fall strategies in addition of training to 
avoid falls. Virtual reality systems should also used. In ad-
vanced ataxia stages, there is no clear benefit of physiother-
apy approaches. However, treadmill training with potential 
weight support may be helpful to increase walking capabili-
ties. Virtual reality systems is of less clear benefit46. More re-
cently, another approach for SCA patients have been stud-
ied using leg cycling therapy. A 4-week cycling regimen could 
normalize the modulation of reciprocal inhibition and func-
tional performance in individuals with SCA47. 
Another study evaluated the effect of inpatient rehabilita-
tion of patient with FRDA. A period of inpatient rehabilitation 
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appears to reverse or halt the downward decline in func-
tion for people with FRDA identified as requiring rehabilita-
tion. Intervention comprised strength and stretching exer-
cises, education, functional and balance retraining, aquatic 
physiotherapy, and development of a home or community 
program48. Another potential strategy recently reported for 
FRDA is a medically supervised endurance training program 
to increase aerobic work capacity and promote weight loss. 
On the other hand, there is insufficient information for 
speech therapy. A recent Cochrane Review concluded that 
there is insufficient evidence from either randomized con-
trol trials or observational studies to determine the effec-
tiveness of any treatment for speech disorder in any of the 
hereditary ataxia syndromes. Nevertheless, speech therapy 
should go beyond assessment. Clinical guidelines for man-
agement of speech, communication and swallowing should 
be performed49. 
DISEASE MODIFYING THERAPIES 
The past few years witnessed remarkable advances in the 
identification of genes and mechanisms underlying inherited 
forms of ataxia. In addition, techniques capable of interfering 
with gene expression are now available, such as RNA interfer-
ence, oligo antisense nucleotides, gene therapy and epigene-
tic-based therapy. Regarding ataxias, no curative treatment 
has emerged, but there are clinical studies currently under-
way using this kind of approaches.
FRDA is probably the single disease within this group 
with the larger number of clinical trials. Most of these stud-
ies investigated drugs with symptomatic effects, but there 
are a few using disease-modifying agents. Experimental data 
indicates that inhibition of histone deacetylase corrects 
this pathological heterochromatinisation and leads to in-
creased expression of frataxin (FXN)50. In this scenario, two 
agents with such epigenetic effects were recently tested in 
patients with FRDA51,52. Libri et al. performed an exploratory 
study with 10 patients with FRDA followed over 8 weeks to 
investigate the effects of high dose nicotinamide (2-8g/day). 
They showed an increase in FXN expression, but no signifi-
cant clinical change51. Soragni et al. assessed the safety and 
efficacy of RG2833 (drug in development) in a neuronal cell 
culture model and in a clinical cohort of 20 patients (Phase I 
study). Authors found dose-dependent increased expression 
of FXN and no significant safety issues after single doses of 
the drug. This was a proof-concept study and no clinical pa-
rameter was reported. These results suggest that epigenetic 
approaches might prove useful for FRDA, but further studies 
are necessary.
Most autosomal dominant ataxias are related to ‘toxic gain 
of function’ of related proteins. Therefore, therapeutic strate-
gies capable of down regulating the expression of the mutant 
genes look promising53. This is particularly evident for the 
polyglutamine diseases (SCA1, 2, 3, 6 and 7). Preclinical studies 
have shown that gene silencing using RNA interference deliv-
ered directly to the cerebellum of SCA3 transgenic mice result-
ed in improvement of motor behavior and neuropathological 
abnormalities54. Scoles et al. showed that intracerebroventric-
ular injections of antisense oligonucleotides against ATXN2 
improved motor function and preserved the firing pattern of 
Purkinje cells in a transgenic mouse model of SCA255. These re-
ports indicate that it is possible to selectively “turn off ” mutant 
alleles (with no modification in the expression of the normal 
allele) and this can attenuate neurodegeneration. In the near 
future, we shall see clinical studies using these gene silenc-
ing techniques, but some important aspects, such as the best 
strategy to deliver the agents to the CNS and the adequate dos-
ing scheme, still need to be addressed. 
Recently, trehalose (Cabaletta®) drug has been tested in 
SCA3. This is a chemical chaperone that protects against 
pathological processes in cells. It has been shown to prevent 
pathological aggregation of proteins within cells in several 
diseases associated with abnormal cellular-protein aggrega-
tion.  A current trial has started in 2014 (ClinicalTrials.gov 
Identifier: NCT02147886).
FuTuRE CLINICAL TRIALS AND PERSPECTIVES 
The remarkable advances in the understanding of inher-
ited ataxias and the appearance of molecular tools capable 
of interfering with gene expression (RNAi, antisense oligo-
nucleotides, HDAC inhibitors) turn the scenario more op-
timistic for the next years. Some phase I clinical trials us-
ing these targeted therapies have been already completed 
(mostly for FRDA) and others are about to begin. We shall 
see an increase in the number of clinical trials for ataxias 
in the near future. This is certainly positive, but it also de-
mands clinical researchers to identify the best outcome 
measures and the more appropriate experimental designs 
Table 3. Rehabilitation strategies for hereditary ataxias.
Rehabilitation therapy Level of evidence / Grade of recommendation
Conventional physical therapy Class II /  B
Treadmill training Class III / C
Relaxation and biofeedback 
training Class III / C
Videogames/computer  
assisted training Class III / C
Supervised sports /  
endurance training Class III / C
Occupational therapy Class III / C
Speech and language therapy No evidence 
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in order to make the studies faster, cheaper and more sen-
sitive56. Most ataxias are very slowly progressive disorders, 
so that clinical scales appear not to be sensitive enough to 
detect longitudinal changes in the short term. Other puta-
tive biomarkers must be identified and validated to speed 
up the therapeutic trials for ataxias.
These therapies will hopefully slow down disease pro-
gression, but those subjects in the late stages of the disease 
might notice no clinical improvement because neurodegen-
eration had already taken place. Therefore, research efforts 
should also focus on regenerative therapies, such as the use 
of stem cells. Early reports raised concerns about the safe-
ty of stem cells in ataxic subjects because of a patient with 
ataxia-telangiectasia who developed a multifocal glioneural 
tumor after intracerebellar injections of human fetal neural 
stem cells57. Several studies are now looking at the effects of 
umbilical mesenchymal stem cells as neuroprotective agents, 
rather than neural stem cells. 
GENETIC COuNSELING AND PREIMPLANTATION 
GENETIC DIAGNOSIS 
Genetic counseling is necessary if parents or close rela-
tives have an inherited disease. Considering the SCAs, the 
risk for a genetic transmission from affected parents is 50%. 
Therefore, many couples with an affected parent decide not 
having children. The last two decades were marked for the 
developmental of the preimplantation genetic diagnosis 
(PGD) which consist in testing the fertilized ova (in vitro fer-
tilization) for the affected gene mutation, and implanting of 
selected healthy embryos ensuring that the pathogenic mu-
tation from parents will be not transmitted to children58. 
PDG has been used for neurological conditions with sev-
eral forms of inheritance, including Huntington`s disease, 
spinal-muscular atrophy, myotonic dystrophy, X-linked dis-
orders, and mitochondrial or chromosomal disorders58,59. 
Clinical applications of PDG for SCA have already been per-
formed with successful results60. 
Several societies for reproductive health have proposed 
that counseling of family members must include PGD in or-
der to prevent transmission of a genetic mutation to future 
generations as part of the standard care58,59. 
FINAL REMARKS   
The hereditary ataxias are a group of neurodegenera-
tive diseases for which no curative treatment is available. 
On the other hand, several symptomatic options used to 
extra-cerebellar signs and rehabilitation therapy may pro-
mote some benefit. Furthermore, neurologists must bear in 
mind that some types of hereditary ataxias such as vitamin 
E and CoQ10 deficiency are treatable. Finally, PGD may work 
as a promising preventive option for hereditary ataxias, par-
ticularly in autosomal dominant forms. Future trials with dis-
ease modifying drugs and cell therapies are expected in the 
following years.   
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